IXICO wins $0.5m imaging contract for Phase 2 Huntington's Disease trial
The war against neurological disease, such as Huntington's, Parkinson's and Alzheimer's, has been fought and largely lost for decades.
However, in late 2023 there was a major medical breakthrough after the FDA approved two Alzheimer's drugs (Biogen's Leqembi and Eli Lilly’s Kisunla), both of which slow a patient's cognitive decline, but require regular brain scans to monitor possible side-effects.
Nonetheless, these early first-generation successes have triggered a surge of new neurological research, reflecting the enormous unmet need whereby tens of millions die annually worldwide. Indeed, stage 3 clinical studies are being conducted in 2025 on next-generation therapeutics (eg Roche's Brain Shuttle technology and Bristol Myers' Cobenfy) - many of which also require detailed MRIs in order to assess a drug’s safety, efficacy and longitudinal performance, as well as to assist in patient trial selection.
Enter (mrkcap £10.2m at 11p) . It is one of the world’s leaders in the highly specialised assessment of brain scans, helping BioPharma and Contract Research Organisations develop new drugs right from the test-tube, through to commercial launch and post marketing surveillance.
What's more, today the company said that it has secured a new Phase 2 Huntington's Disease trial worth >£0.5m over the next 2.5 years. Marvellous news, and another key customer endorsement of 's cutting edge science.
CEO Bram Goorden commenting: "We are delighted to announce our involvement in this Phase 2 clinical trial, which aims to address the urgent need for effective treatments for Huntington's disease. This contract further demonstrates IXICO's expertise in supporting neurodegenerative disease trials, reinforcing our role as a trusted partner for sponsors. Through this work we are proud to continue our support of the Huntington's Disease community, in collaboration with our sponsor, working towards a breakthrough in this challenging field."
Elsewhere, given the H2'24 momentum and >75% FY'25 revenue cover, I suspect there might even be a chance of future upgrades as the year progresses. House broker Cavendish is forecasting Sept FY'25 sales and EBITDA to come in at £6.0m (£5.8m LY) and -£1.4m (£-1.7m) respectively, ending the period with £3m of net cash. In contrast, on a pure run-rate basis, if one simplistically doubled the H2'24 numbers, then FY'25 revenues and EBITDA would be £6.6m and -£0.8m.
Meaning at 11p, the stock trades on a modest 1.2x EV/sales, which looks far too cheap compared to sector peers and the 2023 takeovers of Instem (clinical trial software) and Medica (radiology services) on multiples of 3.0x-3.5x EV/sales. Cavendish has a 24p/share price target.
Follow News & Updates from IXICO:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.